16 October 2020 | News
Second Exclusive License Strengthens Bausch + Lomb's Global Research Focus on Myopia
Image credit- bhvi.org
Bausch Health Companies Inc. and Bausch + Lomb, its leading global eye health business, along with BHVI, an Australian not-for-profit organization with an international focus on vision research, have announced that an affiliate of Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI.
Bausch + Lomb will pair BHVI's novel contact lens design with its leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.
Bausch + Lomb is focused on finding global solutions to treat myopia. The Company also announced earlier this week that one of its affiliates acquired an exclusive license from Eyenovia, Inc. in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12.
"For decades, BHVI has sought solutions to fulfill the unmet needs in the ophthalmic space by innovating commercially relevant technologies, including those specifically developed to help with myopia control," said Frank Back, chairman, BHVI. "Bausch + Lomb's long-standing position as a leader and innovator in eye health makes it the ideal choice for a partner, and we look forward to helping improve the vision of people with myopia around the world through their use of this contact lens design."